-
ASCO 2025 High-Level Dialogue | Prof. Kohei Shitara: New Breakthroughs with T-DXd and CAR-T Cell Therapy Reshape Outcomes in Advanced Gastric Cancer
At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, two studies in the field of targeted therapy for gastric cancer drew significant attention. The world’s first randomized controlled trial (RCT) of CAR-T cell therapy for solid tumors (Abstract 4003) reported positive results, demonstrating both superior efficacy and manageable safety for Claudin 18.2-targeted CAR-T…
-
N Engl J Med | Dr. Jun Shi’s Team Reports First Successful Use of BCMA-Targeted Bispecific T-Cell Engager to Rescue Relapsed Autoimmune Hemolytic Anemia After CD19 CAR T-Cell Therapy
Autoimmune hemolytic anemia (AIHA) has a relatively high incidence (1.8–3.0 per 100,000 person-years) and prevalence (17 per 100,000), with a substantial proportion of patients experiencing refractory or relapsed disease. Nearly 50% of patients relapse multiple times despite receiving first-line glucocorticoids, second-line CD20 monoclonal antibodies, and multiple conventional immunosuppressants, often becoming dependent on long-term drug therapy.…
-
Study Led by Dr. Jianhong Zhong Explores Optimal Duration of Adjuvant Immune Checkpoint Inhibitors After Hepatectomy in High-Risk HCC
Background and Objective Hepatocellular carcinoma (HCC) is among the most common malignancies globally, with a high recurrence rate after resection, especially in patients with risk factors like large tumor size,…
-
2025 Peking University Urology Academic Forum | Prof. Changwen Zhang (The Second Hospital of Tianjin Medical University)
Prof. Changwen Zhang presented a comprehensive update on the Chinese clinical exploration of ADC-based therapies in urothelial carcinoma. His presentation highlighted the promising role of Vedicitumab (RC48), a HER2-targeted ADC,…
Connecting Medical Expertise through Media
